The directors of Asarina Pharma have finally found a buyer for the Tourette’s syndrome treatment sepranolone after securing a bittersweet deal with US firm Relmada Therapeutics which comes four months after the Swedish biotech was forced to close its doors.
The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina
Relmada has acquired sepranolone, a potential blockbuster for the complex neurological condition characterized by involuntary tics, for a bargain €3m from the Stockholm group that went into liquidation late last year.
